Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Study Summary

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors Unresectable Neuroendocrine Tumor Metastatic Gastroenteropancreatic Neuroendocrine Tumor Bronchial Neuroendocrine Tumor Paraganglioma Pheochromocytoma

Interventions / Drugs

[203Pb]VMT-α-NET [212Pb]VMT-α-NET

View on ClinicalTrials.gov ↗

Sponsor

CATX

Perspective Therapeutics

Oncology

D38/100

Study Details

Enrollment260 participants

Primary Completion—

Lead SponsorPerspective Therapeutics

Data Retrieved2026-04-11 04:08:56.505140+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.